HIA
IBRX icon

Harbor Investment Advisory’s ImmunityBio IBRX Stock Holding History

Harbor Investment Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.42K Buy
505
+130
+35% +$984 ﹤0.01% 1139
2026
Q1 		$2.88K Hold
375
– – ﹤0.01% 1084
2025
Q4 		$743 Hold
375
– – ﹤0.01% 1176
2025
Q3 		$923 Buy
+375
New +$966 ﹤0.01% 1132

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbor Investment Advisory's IBRX Position: Q2 2026 in Review

Harbor Investment Advisory increased its ImmunityBio (IBRX) stake by 35% in Q2 2026, buying an estimated $984 and bringing the position to 505 shares worth $4.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Harbor Investment Advisory first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Harbor Investment Advisory held 505 shares of ImmunityBio worth $4.42K as of Q2 2026.
  • Harbor Investment Advisory bought 130 ImmunityBio shares in Q2 2026, an estimated $984.
  • ImmunityBio made up ﹤0.01% of Harbor Investment Advisory's portfolio in Q2 2026, its #1139 holding.
  • Harbor Investment Advisory first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Harbor Investment Advisory's 13F filing for Q2 2026, filed 7 Jul 2026.